Skip to main content

Table 2 Two phase III studies investigating the role of adding oxaliplatin to preoperative chemoradiotherapy in rectal cancer

From: Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology

Study Schema N Grade 3/4
toxicities (%)
LAR pCR Pathological
metastatic
disease (%)
STAR-01 Radiotherapy (59.4 Gy)
and 5-fluorouracil
379 8% 72% 16% 3%
(primary objective:       
overall survival) Radiotherapy, 5-fluorouracil
and oxaliplatin
368 24%
(p < 0.0001)
73% 16% 0.5%
ACCORD 12/0405 Radiotherapy (45 Gy) and
capecitabine
299 11% 73% 14% 4%
PRODIGE 2 (primary       
objective: pCR) Radiotherapy, capecitabine
and oxaliplatin
299 25%
(p < 0.0001)
76% 19% 3%
  1. N: patient number; LAR: low anterior resection; pCR: pathological complete response